Nyman N, Keates E U
Eye Institute, Pennsylvania College of Optometry, Philadelphia.
Optom Vis Sci. 1990 Sep;67(9):705-9. doi: 10.1097/00006324-199009000-00009.
The ability of a new alpha-adrenergic antagonist, dapiprazole, to reverse mydriasis produced by phenylephrine 2.5% or 10%, tropicamide 0.5%, and the combination of phenylephrine 2.5% and tropicamide 0.5% was investigated. A double masked crossover design was used to study both efficacy of mydriatic reversal and time course. The safety of administration was evaluated as well. Subjects were optometry students and their spouses. The results demonstrate that dapiprazole is safe and effective for reversing mydriasis produced by both concentrations of phenylephrine, and partially effective in reversing mydriasis in eyes treated with tropicamide 0.5%, alone, or in combination with 2.5% phenylephrine.
研究了一种新型α-肾上腺素能拮抗剂达哌唑逆转2.5%或10%去氧肾上腺素、0.5%托吡卡胺以及2.5%去氧肾上腺素与0.5%托吡卡胺联合使用所引起的瞳孔散大的能力。采用双盲交叉设计来研究瞳孔散大逆转的疗效和时间进程。同时也评估了给药安全性。受试者为验光专业学生及其配偶
